Large Scale Manufacturing of B43(Anti-CD19)-Genistein for Clinical Trials in Leukemia and Lymphoma
1998; Taylor & Francis; Volume: 29; Issue: 3-4 Linguagem: Inglês
10.3109/10428199809068569
ISSN1042-8194
AutoresDorothea E. Myers, Andrew R. Sicheneder, Dina Clementson, Nancy Dvorak, T.K. Venkatachalam, Alexander Rostov Sev, M Chandan-Langlie, Fatih M. Uckun,
Tópico(s)Transgenic Plants and Applications
ResumoWe have conjugated the murine monoclonal anti-CD 19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD 19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted the manufacturing of a highly purified clinical-grade B43-Genistein preparation. In clonogenic assays, B43-Genistein elicited selective and potent cytotoxicity against CD 19 antigen positive human leukemia cells. To our knowledge, this work represents the first effort of producing a clinical-grade genistein immunoconjugate for treatment of B-lineage leukemia and lymphoma.
Referência(s)